Wang Han-Yun, Chen I-Wen, Lin Cheng-Wei
Division of Endocrinology and Metabolism, Chang Gung Memorial Hospital at Linkou, Taoyuan City.
College of Medicine, Chang Gung University, Taoyuan City.
Sci Prog. 2025 Apr-Jun;108(2):368504251346842. doi: 10.1177/00368504251346842. Epub 2025 May 27.
ObjectiveThere is crosstalk between the thyroid hormone and the renin-angiotensin-aldosterone system, but the clinical application is lacking. Our study aimed to verify the correlation between renin and other thyroid-related biomarkers and their association with treatment prognosis.MethodsThis retrospective study recruited eighty consecutive patients treated for hyperthyroidism in a medical center between 2021 and 2023. Among participants, 53 were newly diagnosed, and 27 were recurrent cases. Laboratory measurements, including renin, aldosterone, and other thyroid-related biomarkers, were assessed, while the associations of biomarkers and clinical symptoms were also analyzed. The clinical variables and biomarkers were entered into the Cox regression model to identify the independent risks associated with time to achieve euthyroidism.ResultsThe correlation matrix showed that free T4 was positively correlated either with T3 ( = 0.755, < 0.001) or renin ( = 0.341, = 0.002) but not with aldosterone ( = 0.055, = 0.631). In ROC analysis for biomarkers and clinical symptoms, either free T4 (AUC = 0.754, < 0.001) or thyroid-stimulating hormone receptor antibody (TSHRAb) (AUC = 0.645, = 0.026) demonstrated effective prediction of tachycardia; however, renin was slightly positive for tachycardia without significance (AUC = 0.580, = 0.233). Regarding thyrotoxic periodic paralysis, the renin showed significant prediction power (AUC = 0.727. = 0.021) rather than free T4 (AUC = 0.543, = 0.748) or TSHRAb (AUC = 0.688, = 0.063). The median time to achieve euthyroidism was 166 days for newly onset patients and 216 days for recurrence, but the time-to-event curves showed no difference (log rank = 0.728). Under Cox regression modeling, TSHRAb was found to independently predict late euthyroidism (Hazard ratio 0.946, 95% confidence interval 0.901-0.993, = 0.026), and the renin had no impact (HR 0.995, 95% CI 0.987-1.003, = 0.215).ConclusionsRenin but not aldosterone was positively correlated with free T4. Certain biomarkers measured at diagnosis were associated with hyperthyroid symptoms. Free T4 and TSHRAb might predict tachycardia, while renin might predict thyrotoxic periodic paralysis; nevertheless, only higher TSHRAb was associated with delayed euthyroid state achievement.
目的
甲状腺激素与肾素-血管紧张素-醛固酮系统之间存在相互作用,但在临床应用方面尚显不足。本研究旨在验证肾素与其他甲状腺相关生物标志物之间的相关性及其与治疗预后的关联。
方法
本回顾性研究纳入了2021年至2023年期间在某医疗中心接受治疗的80例连续的甲亢患者。参与者中,53例为新诊断患者,27例为复发患者。评估了包括肾素、醛固酮和其他甲状腺相关生物标志物在内的实验室测量指标,同时分析了生物标志物与临床症状的关联。将临床变量和生物标志物纳入Cox回归模型,以确定与甲状腺功能正常化时间相关的独立风险因素。
结果
相关矩阵显示,游离T4与T3(r = 0.755,P < 0.001)或肾素(r = 0.341,P = 0.002)呈正相关,但与醛固酮无相关性(r = 0.055,P = 0.631)。在生物标志物和临床症状的ROC分析中,游离T4(AUC = 0.754,P < 0.001)或促甲状腺激素受体抗体(TSHRAb)(AUC = 0.645,P = 0.026)对心动过速具有有效的预测作用;然而,肾素对心动过速呈轻度阳性但无统计学意义(AUC = 0.580,P = 0.233)。对于甲状腺毒症性周期性瘫痪,肾素显示出显著的预测能力(AUC = 0.727,P = 0.021),而非游离T4(AUC = 0.543,P = 0.748)或TSHRAb(AUC = 0.688,P = 0.063)。新发病患者实现甲状腺功能正常化的中位时间为166天,复发患者为216天,但事件发生时间曲线显示无差异(对数秩检验P = 0.728)。在Cox回归模型下,发现TSHRAb可独立预测甲状腺功能正常化延迟(风险比0.946,95%置信区间0.901 - 0.993,P = 0.026),而肾素无影响(HR 0.995,95% CI 0.987 - 1.003,P = 0.215)。
结论
肾素而非醛固酮与游离T4呈正相关。诊断时测量的某些生物标志物与甲亢症状相关。游离T4和TSHRAb可能预测心动过速,而肾素可能预测甲状腺毒症性周期性瘫痪;然而,只有较高的TSHRAb与甲状腺功能正常化延迟相关。